Silexon AI appointed pharmaceutical industry veteran Dr. Jian Liu as CEO

Silexon AI, an industry-leading AI pharmaceutical company, announced that Dr. Jian Liu, an experienced drug R&D scientist, has joined the company as the Chief Executive Officer (CEO) recently.

Dr. Jian Liu brought in more than 20 years of research and leadership experience in innovative drug development. Dr. Liu started his career in the pharmaceutical industry in 2001, joining the medicinal chemistry department in Merck Research Laboratories in Rahway, New Jersey, focusing on innovative small molecule drug discovery. He had been responsible for the invention of 8 PCCs that entered clinical trials for indications including metabolic, cardiovascular, immune, oncology, and pain diseases. Dr. Liu had won the Merck Excellence Award multiple times during his 20 years in Merck. In 2020, Dr. Liu joined the Hengrui Medicine Group US R&D Center Eternity Bioscience Inc. (EBI) in New Jersey as the CSO and Site Head. He successfully carried out rebuilding the drug discovery team and technology platform, and leading the research and development of innovative small molecule drugs for oncology, immune, and neurodegenerative diseases.

Dr. Liu obtained his Ph.D. degree in computational and organic chemistry from the University of California, Los Angeles in 1998. After that, he completed his postdoctoral research work at the University of California, Irvine and the University of Pennsylvania working on peptidomimetics and computer modeling.

We are excited to have Dr. Jian Liu to join Silexon AI to serve as our CEO. As a veteran drug R&D scientist, Dr. Liu has excellent scientific insights in exploring all different fields of pharmaceutical R&D. At the same time, he has outstanding leadership skills based on his management experience from his previous tenures in the two well-known pharmaceutical companies Merck and Hengrui Medicine Group in the United States and China. We believe that under the leadership of Dr. Jian Liu, Silexon AI will continue to grow and further expand the use of cutting-edge AI technology to accelerate drug research and development, leading to innovative drugs for unmet medical needs.